Strategic Partnerships Asylia’s exclusive worldwide license with MD Anderson and a CPRIT seed award validate its platform and create multiple collaboration entry points with leading cancer centers and pharma partners for co-development, licensing, or milestone-driven alliances across cancer and autoimmune indications.

Outsourcing Needs With a lean team and a development-stage pipeline, Asylia is well-positioned to engage CROs and CDMOs for preclinical studies, toxicology, API supply, GMP manufacturing, and IND enabling work, enabling faster milestone achievement without significant headcount expansion.

Platform Enablement The antigen presentation–modulating platform opens demand for specialized translational services such as biomarker discovery, immunoprofiling, companion diagnostics, and data analytics, offering a pathway for CROs and service providers to support assay development and regulatory submissions.

Funding Collaboration Asylia’s CPRIT award suggests accessibility to non-dilutive funding channels; sales conversations can explore advisory services and partnerships that optimize grant strategy, milestone financing, and collaborations to extend development timelines and de-risk clinical programs.

Regional Growth Located in Houston with a strategic tie to MD Anderson, Asylia can benefit from Texas life sciences ecosystem access, regional CRO networks, and manufacturing partners, providing a gateway for regional partnerships and faster market entry in oncology and autoimmunity.